MALARIA,FALCIPARUM

This study tested a new malaria vaccine in 66 healthy adults from Europe and Africa. The goal was to see if the vaccine is safe and how the immune system responds. Participants received three doses of the vaccine over six months, and researchers monitored for side effects and imm…

This study tested a new malaria vaccine (PfSPZ-LARC2) in 75 healthy adults and children in Burkina Faso. The vaccine uses genetically weakened malaria parasites that grow in the liver but cannot cause blood infection. The goal was to see if it is safe and triggers a strong immune…

This study tested a new antibody called TB31F in 167 adults and children in Mali who are often exposed to malaria. The goal was to see if it is safe and can reduce the spread of the malaria parasite to mosquitoes. Participants received either the antibody or a placebo, and resear…

This study looked at whether finding and treating low-density malaria infections (infections with very few parasites) in children can improve their health and well-being over time. 600 children in Tanzania were involved. The goal was to see if this approach reduces illness, anemi…

This study tested a new way to treat uncomplicated malaria by rotating four different drugs across 28 health facilities in western Kenya. Researchers tracked how well the health system handled the change and looked for signs of drug resistance in the malaria parasites. Over 300 p…

This study tested a new experimental malaria drug called MMV367 in 12 healthy adults. Participants were intentionally infected with a controlled, low-level malaria infection to see how well the drug kills the parasite and how safe it is. The goal was to understand the right dose …

This early-stage study tested a single injection of a new long-acting malaria medicine (MMV371) in 32 healthy adults to see if it is safe and how the body processes it. Participants received either the real drug or a placebo, and were monitored for side effects and injection site…